Pembrolizumab in Untreated Extensive SCLC

NCT02580994 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

NETWORK

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

DRUG: Pembrolizumab
DRUG: cis/carboplatin and etoposide

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

[object Object]